<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00344942</url>
  </required_header>
  <id_info>
    <org_study_id>TRICA_L_00872</org_study_id>
    <secondary_id>EudraCT #: 2006-000059-16</secondary_id>
    <nct_id>NCT00344942</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults</brief_title>
  <acronym>RhiCNANI</acronym>
  <official_title>A Randomised, Double-blind, French Multi-centre Study, to Evaluate the Efficacy and Tolerance, in Comparison With Placebo, of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the superiority of the clinical efficacy of 12 weeks' treatment with Nasacort
      versus placebo in adult patients presenting with Chronic Non Allergic and Non Infectious
      Rhinitis
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    patient's recruitment too difficult
  </why_stopped>
  <start_date>April 2006</start_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean global score obtained on the basis of 5 evaluations : nasal obstruction, rhinorrhea, disturbed sense of smell, sneezing, facial heaviness.</measure>
    <time_frame>7 days prior to each visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>list of undesirable events</measure>
    <time_frame>during the treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triamcinolone acetonide</intervention_name>
    <description>220Âµg/day or a double spray into each nostril once daily for 12 weeks'treatment</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>a double spray into each nostril once daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient presenting with Chronic Non Allergic and Non Infectious Rhinitis capable of
             benefiting from corticosteroid therapy administered via the nasal route.

          -  patient with chronic rhinitis of minimum duration 12 weeks, whether or not
             consecutive, per year.

          -  patient with Non Allergic Rhinitis confirmed by negative phadiatop test.

          -  patient presenting a mean global score for the 5 symptoms &gt;= 5 (nasal obstruction,
             rhinorrhea, disturbance of sense of smell, sneezing, facial heaviness), or mean score
             for the 3 main symptoms (nasal obstruction, rhinorrhea, disturbance of sense of smell)
             &gt;= 5 (mean for 7 days prior to visit V0).

          -  patient presenting an inflammation score at anterior rhinoscopy or nasal endoscopy &gt;=
             4.

        Exclusion Criteria:

          -  patient presenting a nasal polyp

          -  patient presenting a severe septal deviation which would interfere with insertion of
             the nasal spray

          -  patient presenting a nasal cavity tumor

          -  patient presenting a sinus infection

          -  patient presenting a history of endonasal surgery

          -  patient presenting a chronic rhinitis of extrinsic origin (drug-related or
             food-related rhinitis) or intrinsic origin (hormonal rhinitis, positional
             rhinitis,atrophic rhinitis, ...)

          -  patient on a program of intensive sports training

          -  patient presenting with : cystic fibrosis, pulmonary mycosis, necrotising
             vascularitis, immotile cilia syndrome, ....

          -  patient presenting with known immunosuppression, lymphoma

          -  patient presenting with a known cardiovascular, neurological or other medically
             significant illness

          -  patient presenting with known renal failure, with known glaucoma, with known drug
             addiction

          -  current antibiotic therapy

          -  corticosteroids administered in the two months prior to admission

          -  patient presenting problems of haemostasis (epistaxis), ophthalmic and/or
             oro-bucco-nasal herpetic infection.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M SEBILLE, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2006</study_first_submitted>
  <study_first_submitted_qc>June 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2006</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

